Product Information
Takinib is a small molecule that is being developed as a treatment for inflammatory bowel disease (IBD). Takinib inhibits the production of pro-inflammatory factors, including cytokines and chemokines. It also reduces the proliferation of cancer cells. Takinib has been shown to be effective in inhibiting cisplatin-induced nephrotoxicity in vivo. It has also been shown to inhibit angiogenesis by suppressing the expression of vascular endothelial growth factor (VEGF) and to induce apoptosis in activated T cells. The molecule also inhibits the expression of molecules such as tumor necrosis factor alpha (TNFα), interleukin 6 (IL6), and monocyte chemoattractant protein 1 (MCP1). The drug's effectiveness against IBD has been demonstrated in a number of clinical trials. The drug has an effective dose of 10mg/kg/day, which is administered orally for up to 12 weeks.
Chemical properties
Technical inquiry about: 3D-LUB55637 Takinib
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
